Stay updated on Pembrolizumab and Pralatrexate in T-Cell Lymphomas Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab and Pralatrexate in T-Cell Lymphomas Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab and Pralatrexate in T-Cell Lymphomas Clinical Trial page

  1. Check
    3 days ago
    No Change Detected
  2. Check
    10 days ago
    Change Detected
    Summary
    The NIH banner about terminology changes and transition updates has been removed from above the study record. The page itself still displays a 403 Forbidden error.
    Difference
    1%
    Check dated 2026-11-07T12:47:43.000Z thumbnail image
  3. Check
    17 days ago
    Change Detected
    Summary
    The site footer revision changes from v3.7.2 to v3.8.0, while the page continues to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-31T13:29:33.000Z thumbnail image
  4. Check
    24 days ago
    Change Detected
    Summary
    A site-wide NIH notice announces a transition in terminology from “Artificial Intelligence” to “Super Intelligence.” It appears above the unavailable study record and does not provide study-specific information.
    Difference
    1%
    Check dated 2026-10-24T13:10:56.000Z thumbnail image
  5. Check
    31 days ago
    Change Detected
    Summary
    The site footer revision changes from v3.7.1 to v3.7.2; the study record page continues to display a 403 error.
    Difference
    0.2%
    Check dated 2026-10-17T14:07:30.000Z thumbnail image
  6. Check
    38 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov footer now identifies the site revision as v3.7.1 instead of v3.7.0.
    Difference
    0.2%
    Check dated 2026-10-10T14:13:51.000Z thumbnail image
  7. Check
    58 days ago
    Change Detected
    Summary
    The page now shows a 403 Forbidden error with a minimal header and a Home button. This replaces the previously visible study record content and related information on the page.
    Difference
    20%
    Check dated 2026-09-19T19:05:42.000Z thumbnail image

Stay in the know with updates to Pembrolizumab and Pralatrexate in T-Cell Lymphomas Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab and Pralatrexate in T-Cell Lymphomas Clinical Trial page.